AOMS1
MCID: ABD014
MIFTS: 65

Abdominal Obesity-Metabolic Syndrome 1 (AOMS1)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 57 12 15
Metabolic Syndrome X 57 12 75 29 55 72
Metabolic Syndrome 44 63 40 17
Abdominal Obesity Metabolic Syndrome 72
Dysmetabolic Syndrome X 12
Metabolic Disease 17
Aoms1 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:14221
ICD9CM 35 277.7
MeSH 44 D024821
NCIt 50 C84442
MedGen 42 C4552048
UMLS 72 C0524620 C2930930

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 57 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to abdominal obesity-metabolic syndrome quantitative trait locus 2 and fatty liver disease, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Topiramate and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and heart, and related phenotypes are hypertension and abdominal obesity

Disease Ontology : 12 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events.

PubMed Health : 63 About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke. The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease. In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries. Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 75 Metabolic syndrome, sometimes known by other names, is a clustering of at least three of the five... more...

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2171)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome quantitative trait locus 2 33.3 SLC2A4 PPARD LEP INS
2 fatty liver disease 32.8 PPARA LEP INS ADIPOQ
3 acquired metabolic disease 32.0 SLC2A4 SERPINE1 RETN PPARG PPARA NOS3
4 liver disease 31.5 PPARA MEG3 LEP INS ADIPOQ
5 sleep apnea 31.2 NOS3 LEP INS GHRL ADIPOQ
6 cerebrovascular disease 31.1 SERPINE1 MEG3 INS ADIPOQ
7 apnea, obstructive sleep 31.1 LEP INS ADIPOQ
8 acanthosis nigricans 31.0 PPARG LEP INS ADIPOQ
9 arteries, anomalies of 30.9 SERPINE1 PPARG NOS3 LEP INS ADIPOQ
10 fatty liver disease, nonalcoholic 1 30.9 RETN PPARA MTTP LEP INS ADIPOQ
11 gestational diabetes 30.8 SLC2A4 RETN LEP INS ADIPOQ
12 hyperinsulinism 30.8 SERPINE1 LEP INS GHRL
13 3-hydroxyacyl-coa dehydrogenase deficiency 30.8 RETN PPARG PPARA NOS3 MIR33A MIR122
14 eating disorder 30.7 LEP GHRL ADIPOQ
15 microvascular complications of diabetes 5 30.7 SERPINE1 NOS3 INS
16 pre-eclampsia 30.7 SERPINE1 NOS3 LEP ADIPOQ
17 liver cirrhosis 30.7 RETN MEG3 LEP ADIPOQ
18 prediabetes syndrome 30.6 PPARG LEP INS ADIPOQ
19 arteriosclerosis 30.6 SERPINE1 PPARG PPARA INS ADIPOQ
20 familial partial lipodystrophy 30.5 PPARG LEP INS
21 lipodystrophy, familial partial, type 1 30.5 PPARG LEP INS
22 hyperthyroidism 30.4 LEP INS GHRL
23 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.3 INS ADIPOQ
24 hyperglycemia 30.3 PPARG NOS3 LEP INS ADIPOQ
25 myocardial infarction 30.2 SERPINE1 RETN NOS3 INS GHRL ADIPOQ
26 lipodystrophy, familial partial, type 3 30.1 PPARG PPARD PPARA
27 coronary heart disease 1 30.1 SERPINE1 RETN NOS3 INS ADIPOQ
28 familial hyperlipidemia 30.0 SERPINE1 PPARA INS
29 uremia 30.0 RETN LEP INS
30 hypertension, essential 30.0 SERPINE1 RETN NOS3 LEP INS ADIPOQ
31 lipodystrophy, congenital generalized, type 1 30.0 LEP INS ADIPOQ
32 acquired generalized lipodystrophy 29.9 RETN PPARG LEP INS ADIPOQ
33 endocrine pancreas disease 29.9 SLC2A4 SERPINE1 LEP INS ADIPOQ
34 inherited metabolic disorder 29.8 LEP INS ADIPOQ
35 glucose intolerance 29.8 SLC2A4 RETN PPARG LEP INS GHRL
36 anorexia nervosa 29.8 RETN LEP GHRL ADIPOQ
37 prader-willi syndrome 29.7 RETN LEP INS GHRL ADIPOQ
38 atherosclerosis susceptibility 29.7 SERPINE1 PPARG PPARA NOS3 INS ADIPOQ
39 proteasome-associated autoinflammatory syndrome 1 29.7 RETN PPARG PPARA INS ADIPOQ
40 lipid metabolism disorder 29.6 SERPINE1 RETN PPARG PPARA MTTP LEP
41 vascular disease 29.6 SERPINE1 RETN PPARG NOS3 INS ADIPOQ
42 overnutrition 29.1 SLC2A4 SERPINE1 RETN PPARG PPARA LEP
43 glucose metabolism disease 28.9 SLC2A4 SERPINE1 RETN PPARG NOS3 LEP
44 diabetes mellitus 28.1 SLC2A4 SERPINE1 RETN PPARG PPARA NOS3
45 diabetes mellitus, noninsulin-dependent 27.9 SLC2A4 SERPINE1 SCD RETN PPARG PPARD
46 body mass index quantitative trait locus 11 27.6 SLC2A4 SERPINE1 SCD RETN PPARG PPARD
47 abdominal obesity-metabolic syndrome 3 12.5
48 mineral metabolism disease 12.4
49 plasma protein metabolism disease 12.2
50 histidine metabolism disease 12.2

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

32
# Description HPO Frequency HPO Source Accession
1 hypertension 32 HP:0000822
2 abdominal obesity 32 HP:0012743

Symptoms via clinical synopsis from OMIM:

57
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM:

605552

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.32 ADIPOQ GHRL HSD11B1 INS LEP NOS3
2 homeostasis/metabolism MP:0005376 10.28 ACADM ADIPOQ GHRL HSD11B1 INS LEP
3 cardiovascular system MP:0005385 10.26 ACADM ADIPOQ ETFDH HSD11B1 INS LEP
4 growth/size/body region MP:0005378 10.21 ADIPOQ HSD11B1 INS LEP MTTP NOS3
5 behavior/neurological MP:0005386 10.15 ADIPOQ GHRL HSD11B1 INS LEP NOS3
6 immune system MP:0005387 10.15 ADIPOQ HSD11B1 INS LEP NOS3 PPARA
7 endocrine/exocrine gland MP:0005379 10.11 ADIPOQ GHRL HSD11B1 INS LEP NOS3
8 liver/biliary system MP:0005370 10.1 ACADM ADIPOQ HSD11B1 INS LEP MTTP
9 integument MP:0010771 9.97 ADIPOQ HSD11B1 INS LEP PPARA PPARD
10 mortality/aging MP:0010768 9.93 ACADM ADIPOQ ETFDH INS LEP MTTP
11 muscle MP:0005369 9.65 ACADM ADIPOQ HSD11B1 INS LEP NOS3
12 renal/urinary system MP:0005367 9.17 ADIPOQ INS LEP NOS3 PPARG SCD

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

PubMed Health treatment related to Abdominal Obesity-Metabolic Syndrome 1: 63

Healthy lifestyle changes are the first line of treatment for metabolic syndrome. Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking. If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure, high triglycerides, low HDL cholesterol, and high blood sugar. Blood-thinning medicines, such as aspirin, also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome.

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 827)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
6
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
7
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
8
Rufinamide Approved Phase 4 106308-44-5 129228
9
Nitrazepam Approved Phase 4 146-22-5 4506
10
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
11
Stiripentol Approved Phase 4 49763-96-4
12
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
13
Vigabatrin Approved Phase 4 60643-86-9, 68506-86-5 5665
14
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
15
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
16
Ethosuximide Approved Phase 4 77-67-8 3291
17
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
18
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
19
Fenofibrate Approved Phase 4 49562-28-9 3339
20
Nitric Oxide Approved Phase 4 10102-43-9 145068
21
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
22
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
23
Galantamine Approved Phase 4 357-70-0 9651
24
Magnesium oxide Approved Phase 4 1309-48-4 14792
25
Ramipril Approved Phase 4 87333-19-5 5362129
26
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
27
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
28
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
29
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
30
Trandolapril Approved Phase 4 87679-37-6 5484727
31
Febuxostat Approved Phase 4 144060-53-7 134018
32
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
33
Atenolol Approved Phase 4 29122-68-7 2249
34
Nifedipine Approved Phase 4 21829-25-4 4485
35
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
36
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
37
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
38
Liraglutide Approved Phase 4 204656-20-2 44147092
39
Clozapine Approved Phase 4 5786-21-0 2818
40
Bisoprolol Approved Phase 4 66722-44-9 2405
41
Infliximab Approved Phase 4 170277-31-3
42
Glucagon Approved Phase 4 16941-32-5
43
Doxazosin Approved Phase 4 74191-85-8 3157
44
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
45
Colchicine Approved Phase 4 64-86-8 6167 2833
46
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
47
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
48
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
49
Lorazepam Approved Phase 4 846-49-1 3958
50
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767

Interventional clinical trials:

(show top 50) (show all 2639)
# Name Status NCT ID Phase Drugs
1 Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
2 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
3 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
4 Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension Unknown status NCT00790946 Phase 4 Valsartan
5 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
6 The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
7 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
8 Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
9 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
10 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
11 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
12 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
13 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
14 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
15 Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
16 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
17 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
18 A Multicenter, Eight Weeks Treatment, Single Step Titration, Open Label Study Assessing the Percentage of Korean Diabetic Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Dose 10mg, 20mg, 40mg Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
19 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
20 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
21 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study) Unknown status NCT01736202 Phase 4
22 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
23 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
24 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
25 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
26 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
27 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo
28 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
29 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
30 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
31 A Double Blind Randomized Control Trial to Study the Effect of Long Term Vitamin D Supplementation on Peripheral Insulin Sensitivity in Apparently Healthy Middle Aged Centrally Obese Adults Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
32 Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
33 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
34 A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years Unknown status NCT02205931 Phase 4 Antiepileptic drug therapy
35 PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
36 A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
37 A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome) Completed NCT00272311 Phase 4 Aspirin
38 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
39 Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
40 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4 fenofibrate;niacin;rosiglitazone
41 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
42 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome Completed NCT00138528 Phase 4 Fluvastatin
43 The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed NCT00515021 Phase 4 Eplerenone (Morning);Eplerenone (Night-time)
44 The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
45 A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension Completed NCT01138423 Phase 4 Aliskiren;Moxonidine;Hydrochlorothiazide;Placebo (for aliskiren);Placebo (for moxonidine and hydrochlorothiazide)
46 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4 Irbesartan;Hydrochlorothiazide
47 A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
48 The Effect of Rosiglitazone on Adipocyte-derived Cytokines in Nondiabetics With the Metabolic Syndrome Completed NCT00364221 Phase 4 Rosiglitazone
49 A Multicenter, Double Blind, Randomized Study With Two Parallel Groups Comparing The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome Completed NCT00241150 Phase 4 VALSARTAN
50 Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT) Completed NCT00815659 Phase 4 rosuvastatin

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 29 MTTP

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

41
Liver, Endothelial, Heart, Ovary, Prostate, Bone, Testes

Publications for Abdominal Obesity-Metabolic Syndrome 1

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 973)
# Title Authors PMID Year
1
Prospective analysis of the insulin-resistance syndrome (syndrome X). 9 8
1587398 1992
2
Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening. 71
22947299 2012
3
Screening of 336 single-nucleotide polymorphisms in 85 obesity-related genes revealed McKusick-Kaufman syndrome gene variants are associated with metabolic syndrome. 8
19247371 2009
4
Hepatic insulin resistance directly promotes formation of cholesterol gallstones. 8
18587407 2008
5
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. 8
18305138 2008
6
Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. 8
17273170 2007
7
Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. 71
16596417 2006
8
Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. 8
16391564 2006
9
The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. 8
16446448 2006
10
A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. 8
16721486 2006
11
Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. 71
16204371 2005
12
Retinoid x receptor heterodimers in the metabolic syndrome. 8
16093469 2005
13
Association between common polymorphisms of the proopiomelanocortin gene and body fat distribution: a family study. 8
16046320 2005
14
Association of the metabolic syndrome with intracranial atherosclerotic stroke. 8
16043803 2005
15
Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism. 8
15919835 2005
16
Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. 71
15867853 2005
17
Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. 8
15562396 2004
18
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. 71
15500895 2004
19
Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. 8
15309680 2004
20
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. 8
14557872 2003
21
The Gly16-->Arg16 and Gln27-->Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men. 71
14557466 2003
22
Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. 8
12970275 2003
23
Association of polymorphisms in the estrogen receptor alpha gene with body fat distribution. 8
12917706 2003
24
Association of low interleukin-10 levels with the metabolic syndrome in obese women. 8
12629085 2003
25
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. 8
12588201 2003
26
A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. 71
12161552 2002
27
Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. 71
12050239 2002
28
The 27Glu polymorphism of the beta2-adrenergic receptor gene interacts with physical activity influencing obesity risk among female subjects. 71
12030897 2002
29
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. 8
11790215 2002
30
A transgenic model of visceral obesity and the metabolic syndrome. 8
11739957 2001
31
The effect of the Gly16Arg polymorphism of the beta(2)-adrenergic receptor gene on plasma free fatty acid levels is modulated by physical activity. 71
11739457 2001
32
A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. 8
11734540 2001
33
Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. 71
11502844 2001
34
Cardiovascular morbidity and mortality associated with the metabolic syndrome. 8
11315831 2001
35
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. 8
11121050 2000
36
Association of glutamine 27 polymorphism of beta 2 adrenoceptor with reported childhood asthma: population based study. 71
9522789 1998
37
Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. 71
9399946 1997
38
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. 71
9399966 1997
39
The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. 71
9275150 1997
40
Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. 71
7706471 1995
41
Metabolic implications of body fat distribution. 8
1773700 1991
42
Banting lecture 1988. Role of insulin resistance in human disease. 8
3056758 1988
43
MiR-33 contributes to the regulation of cholesterol homeostasis. 88
20466885 2010
44
Altered body composition in preterm infants at hospital discharge. 9 38
19594474 2009
45
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. 9 38
18049445 2007
46
[The metabolic syndrome X or insulin resistance syndrome]. 9 38
17304724 2007
47
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. 9 38
16941796 2006
48
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). 9 38
17119268 2006
49
Expression analysis of genes involved in fat assimilation in human monocytes. 9 38
16801219 2006
50
Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. 9 38
16641887 2006

Variations for Abdominal Obesity-Metabolic Syndrome 1

ClinVar genetic disease variations for Abdominal Obesity-Metabolic Syndrome 1:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 NOS3 NM_000603.5(NOS3): c.-51-762C> T single nucleotide variant protective rs2070744 7:150690079-150690079 7:150992991-150992991
2 GHRL NM_001134944.2(GHRL): c.178C> A (p.Leu60Met) single nucleotide variant Pathogenic,risk factor rs696217 3:10331457-10331457 3:10289773-10289773
3 GHRL NM_001134944.2(GHRL): c.116G> A (p.Arg39Gln) single nucleotide variant risk factor rs34911341 3:10331519-10331519 3:10289835-10289835
4 PTS NM_000317.2(PTS): c.(?_-1)_(*1_?)del deletion Likely pathogenic
5 LMNA NM_170707.4(LMNA): c.1892G> A (p.Gly631Asp) single nucleotide variant Uncertain significance rs267607648 1:156108472-156108472 1:156138681-156138681
6 NOS3 NM_000603.5(NOS3): c.894T> G (p.Asp298Glu) single nucleotide variant Benign rs1799983 7:150696111-150696111 7:150999023-150999023
7 NOS3 NM_000603.5(NOS3): c.774T> C (p.Asp258=) single nucleotide variant Benign rs1549758 7:150695726-150695726 7:150998638-150998638

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 SLC2A4 SCD PPARG PPARD PPARA NOS3
2
Show member pathways
12.7 SLC2A4 SCD PPARG PPARD PPARA LEP
3
Show member pathways
12.63 SLC2A4 RETN LEP INS ADIPOQ
4 12.41 SLC2A4 SCD PPARG INS ADIPOQ
5
Show member pathways
12.29 SLC2A4 SCD PPARG LEP INS ADIPOQ
6
Show member pathways
12.07 SLC2A4 NOS3 LEP INS
8
Show member pathways
11.85 SLC2A4 PPARA NOS3 INS
9 11.8 SERPINE1 NOS3 INS
10
Show member pathways
11.73 SLC2A4 INS ADIPOQ
11
Show member pathways
11.7 PPARG PPARD PPARA
12 11.62 SCD PPARG MIR33A INS
13 11.57 SLC2A4 PPARA LEP ADIPOQ
14 11.44 SLC2A4 SERPINE1 SCD RETN PPARG PPARD
15 11.31 SCD PPARG PPARD PPARA ADIPOQ ACADM
16 11.21 PPARG PPARD PPARA MIR33A
17 11.07 PPARG LEP ADIPOQ
18 10.93 SCD PPARA MIR33A
19 10.9 SLC2A4 PPARG LEP ADIPOQ
20 10.8 SLC2A4 INS

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Cellular components related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor complex GO:0090575 8.8 PPARG PPARD PPARA

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.97 PPARG PPARD PPARA ACADM
2 negative regulation of cell growth GO:0030308 9.89 PPARG PPARD MEG3
3 response to ethanol GO:0045471 9.88 SLC2A4 LEP ADIPOQ
4 wound healing GO:0042060 9.86 PPARD PPARA INS
5 cellular response to insulin stimulus GO:0032869 9.86 SLC2A4 PPARG ADIPOQ
6 negative regulation of inflammatory response GO:0050728 9.86 PPARD PPARA GHRL ADIPOQ
7 response to nutrient GO:0007584 9.85 PPARG LEP ADIPOQ
8 response to insulin GO:0032868 9.83 RETN PPARA LEP
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 PPARD LEP INS
10 positive regulation of cold-induced thermogenesis GO:0120162 9.83 SCD LEP GHRL ADIPOQ
11 regulation of blood pressure GO:0008217 9.81 PPARG NOS3 LEP
12 regulation of lipid metabolic process GO:0019216 9.81 PPARG PPARD PPARA ACADM
13 response to nutrient levels GO:0031667 9.8 LEP GHRL ADIPOQ
14 circadian rhythm GO:0007623 9.8 SERPINE1 MTTP LEP ADIPOQ
15 fatty acid metabolic process GO:0006631 9.8 SCD PPARG PPARD PPARA ACADM
16 steroid hormone mediated signaling pathway GO:0043401 9.79 PPARG PPARD PPARA
17 response to activity GO:0014823 9.77 PPARD LEP ADIPOQ
18 placenta development GO:0001890 9.77 PPARG PPARD LEP
19 intracellular receptor signaling pathway GO:0030522 9.76 PPARG PPARD PPARA
20 lipid metabolic process GO:0006629 9.76 SCD PPARG PPARD PPARA MTTP LEP
21 negative regulation of blood pressure GO:0045776 9.74 PPARA NOS3 ADIPOQ
22 response to vitamin A GO:0033189 9.71 PPARG PPARD
23 regulation of nitric-oxide synthase activity GO:0050999 9.71 NOS3 LEP
24 response to lipid GO:0033993 9.71 PPARG PPARD PPARA
25 positive regulation of insulin receptor signaling pathway GO:0046628 9.7 LEP INS
26 positive regulation of cellular protein metabolic process GO:0032270 9.7 INS ADIPOQ
27 negative regulation of collagen biosynthetic process GO:0032966 9.7 PPARG PPARD
28 fatty acid catabolic process GO:0009062 9.69 PPARD LEP
29 negative regulation of gluconeogenesis GO:0045721 9.69 INS ADIPOQ
30 fatty acid transport GO:0015908 9.69 PPARD PPARA
31 regulation of gluconeogenesis GO:0006111 9.68 LEP ACADM
32 negative regulation of smooth muscle cell migration GO:0014912 9.68 SERPINE1 PPARD
33 negative regulation of pri-miRNA transcription by RNA polymerase II GO:1902894 9.67 PPARD PPARA
34 hormone-mediated signaling pathway GO:0009755 9.67 PPARG PPARD PPARA GHRL
35 fatty acid beta-oxidation using acyl-CoA dehydrogenase GO:0033539 9.66 ETFDH ACADM
36 adult feeding behavior GO:0008343 9.66 LEP GHRL
37 negative regulation of appetite GO:0032099 9.65 PPARA LEP